MFLRC Academy is live. On-demand regulatory training. Lesson 1 is free. Explore→

MFLRC Academy — on-demand training in Health Canada licensing, GMP and quality systems. Browse courses →

MFLRC - MF License & Regulatory Consultants

September 15, 2026 · Regulatory Affairs

Everything That Changed on 1 October 2026: A Compliance Guide for Canadian Licence Holders

By Mussarat Fatima

Regulatory AffairsComplianceRegulationsPharmaceuticals
Everything That Changed on 1 October 2026: A Compliance Guide for Canadian Licence Holders

The countdown is over. As of today, 1 October 2026, a cluster of regulatory instruments that Canadian licence holders have been tracking for months is in force. This is no longer a planning exercise. If you hold a Health Canada licence for cannabis, drugs, natural health products or medical devices, at least one of these changes now applies to you, and several may apply at once. The question an inspector will ask from this point forward is not whether you knew the changes were coming. It is whether you can show that your standard operating procedures, records and training already reflect them.

This article is the day-one map. It sets out what changed on 1 October 2026, what the September run-up required, and the single checklist that tells you whether your licence is ready to withstand scrutiny now rather than next quarter. We have published detailed articles on each instrument, and this page ties them together so you can confirm your exposure in one place and close any remaining gap before it becomes a finding.

Executive Summary

Seven changes now shape compliance for Canadian licence holders as of 1 October 2026. The Controlled Substances Regulations (SOR/2025-242) and the cannabis harmonization amendments (SOR/2025-244) are in force. Health Canada's revised summary reports guidance and its reduced foreign action notification list under section C.01.050 now apply. The PIC/S recommendation on qualification and validation, PI 006-4, has replaced PI 006-3. Health Canada's implementation of ICH E6(R3) Good Clinical Practice reaches its Canadian transition date for sponsors and sites. And the United States FDA priority review voucher fee for fiscal year 2027 is now effective. The September run-up deadlines, including the 30 September cannabis annual regulatory fee, have passed, so a missed filing is now a live problem rather than a looming one. Work through the day-one checklist below, confirm which items apply to your licence, and prioritize evidence that the change is already embedded in your quality system.

What Changed on 1 October 2026?

In short: seven instruments now govern licence holders across cannabis, controlled substances, pharmaceutical post-market reporting, validation practice, clinical trials and cross-border user fees. The table below is the at-a-glance version. Each row is expanded in its own section, with a link to the detailed article.

InstrumentWho it affectsWhat is now in force
SOR/2025-242 Controlled Substances RegulationsDealers, licensed producers, controlled-substance handlersA consolidated controlled substances framework is in force
SOR/2025-244 Cannabis Regulations amendmentsCannabis licence holdersHarmonization with the controlled substances rules is in effect
Summary reports guidanceDIN and NPN holdersThe revised submission trigger now applies
Foreign action notification list (C.01.050)Drug establishment licence and market authorization holdersThe recognized list now stands at 22 authorities
PIC/S PI 006-4GMP-regulated manufacturersA rewritten qualification and validation recommendation has replaced PI 006-3
ICH E6(R3) Good Clinical PracticeClinical trial sponsors, sites and QAHealth Canada's modernized GCP expectations reach their transition date
FDA priority review voucher fee, FY2027Sponsors redeeming a voucher, including Canadian onesThe fee of $1,798,596 is now effective through 30 September 2027

Cannabis and Controlled Substances: SOR/2025-244 and SOR/2025-242 Are In Force

What it is: the Controlled Substances Regulations (SOR/2025-242) consolidate several older regulatory schemes into one modernized framework, and the cannabis amendments (SOR/2025-244) align the Cannabis Regulations with that framework. Both are in force as of 1 October 2026. SOR/2025-244 was registered on 28 November 2025 and published in the Canada Gazette, Part 2, on 17 December 2025, so the text has been settled for months and today is the operative date.

Why it matters: harmonization means your cannabis standard operating procedures, security controls and record-keeping must now reflect the new controlled substances language, not the old one. An inspector arriving this quarter will expect to see the updated framework already in your documents. For a section-by-section view, see our guide to every SOR/2025-244 cannabis change in force 1 October 2026, and for the dealer and manufacturer side, read what the new Controlled Substances Regulations (SOR/2025-242) mean for manufacturers and dealers.

What to do now: confirm that your SOPs, quality agreements and security procedures already cite the current instruments, that references to superseded regulations have been removed, and that your quality assurance person has signed off on the review. If staff who handle controlled substances or cannabis were not retrained before today, treat that as an open gap and close it this week. Training that lands after the effective date is the kind of timing an inspector notices.

Summary Reports: The Revised Submission Trigger Now Applies

What it is: Health Canada's revised summary reports guidance is in force for drug identification number and natural product number holders. The duty to prepare a summary report on a defined cycle has not gone away. What has changed is the trigger for when you must submit that report to Health Canada. The obligation to keep the safety analysis current is unchanged, so a holder who reads the update as a reason to stop preparing reports has misread it. Our full explainer covers what DIN and NPN holders must change under the summary reports guidance.

Why it matters and what to do: a summary report is a signal-detection document, and inspectors look for evidence that the review actually happened on schedule. Confirm your SOP names the correct preparation cycle, that the responsible person is assigned, and that the submission trigger in your procedure matches the revised guidance. Do not let a change in submission mechanics erode the underlying pharmacovigilance discipline. The Health Canada guidance on annual and summary reports is the primary reference to reconcile against.

The Foreign Action Notification List Now Stands at 22 Authorities

What it is: the list of foreign regulatory authorities whose actions you must notify Health Canada about, under section C.01.050 of the Food and Drug Regulations, has been reduced from 41 authorities across 35 jurisdictions to 22 authorities across 13. A shorter list does not mean a lighter duty. It means the set of triggering authorities has been redefined, and your internal notification procedure must match the new set exactly. See our detailed piece on the foreign action notification list moving from 41 authorities to 22.

What to do now: confirm the authority list embedded in your foreign-action reporting SOP reflects the 22 recognized authorities. If your procedure simply says the authorities on the Health Canada list, make sure staff know where the current list lives and check it, because a reduced list changes which overseas actions you are obliged to report within the required timeframe.

PIC/S PI 006-4 Has Replaced PI 006-3

What it is: PIC/S PI 006-4, the recommendation on qualification and validation, is in force as of 1 October 2026 and replaces PI 006-3, which dated from September 2007. The new single document folds in the concepts introduced when Annex 15 was revised in 2015, with quality risk management under ICH Q9 running through every section. It treats qualification and validation as lifecycle activities scaled by risk, and adds prequalification stages, performance qualification, ongoing process verification, transport verification, packaging validation, utility qualification and test method validation. The recommendation is published by PIC/S.

Why it matters and what to do: inspectors from PIC/S participating authorities, including Health Canada, now apply the modernized expectations. Review your validation master plan against the lifecycle structure, confirm your risk rationales are documented rather than assumed, and check that ongoing process verification is a live programme and not a one-time exercise. This change sits alongside the EU GMP updates we track, including the revised Annex 19 on reference and retention samples.

ICH E6(R3) Good Clinical Practice Reaches Its Canadian Transition Date

What it is: Health Canada's implementation of ICH E6(R3), the modernized Good Clinical Practice guideline, reaches a key Canadian transition point on 1 October 2026. E6(R3) reframes GCP around quality by design, risk proportionality and fitness for purpose rather than a fixed checklist, and it applies to sponsors, investigators, sites and the quality staff who support trials. Our readiness guide explains the quality-by-design and risk-proportionality plan for the 1 October 2026 deadline.

Why it matters and what to do: if you sponsor or support clinical trials in Canada, your trial oversight, monitoring plans, essential records and investigator agreements should already reflect the risk-based approach. Confirm your GCP training is current, that your quality management of the trial is documented as a proportionate system, and that roles and responsibilities are defined in line with the revised guideline. Where cannabis, natural health product or drug development intersects with trials, the same discipline applies.

FDA Priority Review Voucher Fee for FY2027 Is Now Effective

What it is: the United States FDA has set the priority review voucher fee for fiscal year 2027 at $1,798,596. The rate is effective on 1 October 2026 and remains in effect through 30 September 2027. It applies to any eligible human drug or biological product application received on or after 1 October 2026 that is submitted with a tropical disease, rare pediatric disease or material threat medical countermeasure voucher, and it is payable in addition to the normal user fee. The amount and dates are set in the FDA notice in the Federal Register.

Why it matters and what to do: the fee binds any sponsor, including Canadian companies, that intends to redeem a voucher in a United States application during FY2027. There is no waiver, exemption, reduction or refund available for this fee. If a submission using a voucher is realistic in your plan, budget the amount and align it with the 90-day notification-of-intent requirement that precedes the application.

The September Run-Up Has Passed: What To Do If You Missed a Date

Why it matters: five deadlines fell in the ten days before 1 October, and one of them, the cannabis annual regulatory fee, carries a mandatory refusal if the medical-sale exemption declaration was late. Those dates are now behind you, so the task is no longer to plan for them. It is to confirm each was met and to act quickly where one was not.

Date (now passed)EventIf you missed it
20 September 2026Consultation on the draft NHP Quality Guide version 4 closedThe comment window is closed; prepare for the final guide instead
24 September 2026EudraLex GMP Annex 19 became applicableAlign reference and retention sample procedures now if you supply the EU market
25 September 2026Health Canada recognized standards feedback closed; the list moved to continuous updatesMonitor the list year-round; it no longer has a single annual window
29 September 2026US import restriction on listed Canadian goods took effectReview admissibility before any US-bound shipment of affected products
30 September 2026Cannabis annual regulatory fee and medical-sale exemption declaration due through CTLSA late exemption declaration must be refused; confirm your filing and keep proof

The 30 September cannabis deadline is the one to verify first. Health Canada must refuse a late medical-sale exemption declaration, so if the filing slipped, you may be exposed to the full annual fee and should take advice immediately. Our guide to the cannabis annual regulatory fee and the medical exemption declaration walks through the CTLS steps and what proof of submission to retain.

Day-One Compliance Checklist

Use this list to confirm which items apply to your licence and whether each change is already embedded in your quality system, not merely understood.

  • Cannabis and controlled substances SOPs updated to reflect SOR/2025-242 and SOR/2025-244, with superseded references removed.
  • Staff who handle controlled substances or cannabis retrained on the harmonized requirements, with dated training records on file.
  • Summary report SOP checked against the revised preparation cycle and submission trigger for your DIN or NPN products.
  • Foreign-action reporting procedure updated to the current list of 22 recognized authorities under C.01.050.
  • Validation master plan and ongoing process verification reviewed against PIC/S PI 006-4 lifecycle expectations.
  • Clinical trial oversight, monitoring and training aligned with ICH E6(R3) risk-proportionate GCP, where you sponsor or support trials.
  • FY2027 priority review voucher fee of $1,798,596 budgeted if a US voucher submission is planned.
  • Cannabis annual regulatory fee and medical-sale exemption declaration confirmed filed through CTLS, with proof retained.
  • Reference and retention sample procedures aligned with EudraLex Annex 19, if you supply the EU market.

Common Mistakes

  • Treating 1 October as a future date. The instruments are in force now, so the test shifts from readiness to evidence of compliance already in place.
  • Reading a shorter foreign-action list as a lighter duty. The set of triggering authorities changed; the obligation to notify did not.
  • Treating the summary reports change as permission to stop preparing reports. The duty to prepare and keep the analysis current is unchanged.
  • Retraining staff after the effective date. Training that lands after today is a finding waiting to happen; document it as a corrective action if it was late.
  • Assuming PI 006-4 is a light edit of PI 006-3. It is a full rewrite with new lifecycle stages and a risk-based structure.
  • Forgetting that a missed 30 September cannabis filing has no grace period. A late medical-sale exemption declaration must be refused.

Frequently Asked Questions

Is SOR/2025-244 in force now?

Yes. SOR/2025-244, the cannabis harmonization amendments, came into force on 1 October 2026. It was registered on 28 November 2025 and published in the Canada Gazette, Part 2, on 17 December 2025. The related Controlled Substances Regulations, SOR/2025-242, came into force on the same date.

What should I do if I missed the 30 September cannabis fee deadline?

Act immediately. The cannabis annual regulatory fee and the medical-sale exemption declaration were due through the Cannabis Tracking and Licensing System by 30 September 2026, and Health Canada must refuse a late exemption declaration. A missed filing can expose you to the full annual fee, so confirm your submission status, keep any proof you have, and seek advice before the next billing cycle.

Did the summary reports duty disappear on 1 October?

No. The duty to prepare a summary report on a defined cycle and to keep the safety analysis current is unchanged. What changed is the trigger for when you must submit the report to Health Canada. Confirm your SOP names the correct preparation cycle, assigns a responsible person, and reflects the revised submission trigger.

What is the FDA priority review voucher fee for FY2027?

The FDA priority review voucher fee for fiscal year 2027 is $1,798,596. It is effective on 1 October 2026 and remains in effect through 30 September 2027, and it applies to any eligible application received on or after 1 October 2026 that uses a voucher. There is no waiver, exemption or refund for this fee.

How is PIC/S PI 006-4 different from PI 006-3?

PI 006-4 is a complete rewrite that replaces the 2007 PI 006-3. It reflects the 2015 revision of Annex 15, embeds quality risk management under ICH Q9, and adds prequalification, performance qualification, ongoing process verification, transport verification, packaging validation, utility qualification and test method validation as lifecycle activities scaled by risk. It came into force on 1 October 2026.

What does the ICH E6(R3) transition mean for my trials?

Health Canada's implementation of ICH E6(R3) reaches a key Canadian transition point on 1 October 2026. In practice, sponsors and sites should already run trial oversight, monitoring and quality management as a risk-proportionate system, keep GCP training current, and define roles and responsibilities in line with the revised guideline. Our readiness guide sets out a practical plan.

How MFLRC Can Help

MFLRC turns a cluster like this into a plan you can defend. We run a gap assessment against the full 1 October set and tell you, in writing, which instruments apply to your licence and what is still missing. We update SOPs and documentation, prepare and reconcile summary reports, support CTLS filing for the cannabis fee and exemption declaration, align validation master plans with PI 006-4, and provide quality assurance person services and inspection-readiness reviews. Explore our regulatory affairs, licensing and import and export services, our audit services, and our cannabis and hemp support. If you want a head start on documentation, our guide to writing SOPs that pass a Health Canada inspection and our GMP inspection-readiness self-assessment are good first steps.

These changes took effect today. Book an MFLRC post-implementation gap assessment and we will tell you which of them apply to your licence and what to fix first, before your next inspection.

Conclusion

1 October 2026 is a rare convergence: seven instruments, several sectors, one date. None of them is unmanageable on its own. The risk now is not missing the date, because it has arrived. It is discovering during an inspection that a change was understood but never written into an SOP, or that training happened after the fact. Confirm your exposure against the day-one checklist, protect any late cannabis filing first, and make sure every applicable change is visible in your quality system as evidence, not just intent. For the enforcement backdrop to all of this, see our analysis of Health Canada's POL-0001 version 10 enforcement policy.

Sources and References

Share with others

Tags

Health CanadaCannabisControlled SubstancesSOR/2025-242ComplianceCannabis Annual FeesUser FeesForeign Action ReportingInspection Readiness
Book a consultation